UPADACITINIB TARTRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H19F3N6O.C4H6O6.4H2O
Molecular Weight	602.5155
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.CC[C@@H]1CN(C[C@@H]1C2=CN=C3C=NC4=C(C=CN4)N23)C(=O)NCC(F)(F)F

InChI

InChIKey=LATZVDXOTDYECD-ARKNDKGZSA-N

InChI=1S/C17H19F3N6O.C4H6O6.4H2O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15;5-1(3(7)8)2(6)4(9)10;;;;/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27);1-2,5-6H,(H,7,8)(H,9,10);4*1H2/t10-,11+;1-,2-;;;;/m11..../s1

HIDE SMILES / InChI

Molecular Formula	C17H19F3N6O
Molecular Weight	380.3676
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H6O6
Molecular Weight	150.0868
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.abbvie.com/our-science/pipeline/upadacitinib.html | https://ankylosingspondylitisnews.com/upadacitinib-abt-494/ | https://www.ncbi.nlm.nih.gov/pubmed/29076110 | https://www.ncbi.nlm.nih.gov/pubmed/27577235

Upadacitinib (ABT-494) is a Janus kinase 1 (JAK1) inhibitor currently being developed by AbbVie for the treatment of rheumatoid arthritis (RA), Crohn’s disease, ulcerative colitis, atopic dermatitis, and psoriatic arthritis. It is also being investigated as a potential treatment for people with active ankylosing spondylitis (AS). Currently, upadacitinib is being evaluatedin six global phase III studies in RA and twophase III studies in psoriatic arthritis (PsA), inaddition to phase II studies in Crohn’s disease and atopicdermatitis and a combined phase II/III study inulcerative colitis. Upadacitinib is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tyrosine-protein kinase JAK1 39 Target ID: CHEMBL2835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27577235	Inhibitor 8504		43.0 nM [IC50]
Tyrosine-protein kinase JAK2 59 Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27577235	Inhibitor 8504		200.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Rheumatoid arthritis 320 Sources: https://www.abbvie.com/our-science/pipeline/upadacitinib.html https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/31130260	Primary		Approved 8583	RINVOQ Approved Use RINVOQ is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Launch Date 2019

C_max

Value	Dose	Co-administered	Analyte	Population
63.7 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29688617	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		UPADACITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
491 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29688617	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		UPADACITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
18.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29688617	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		UPADACITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
48% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf			UPADACITINIB plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31786154	unhealthy, 39.9 years (range: 18-75 years) Health Status: unhealthy Age Group: 39.9 years (range: 18-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/31786154	Other AEs: Anemia, Neutropenia... Other AEs: Anemia (2.4%) Neutropenia (4.8%) Atopic dermatitis (9.5%) Acne (14%) Headache (9.5%) Nasopharyngitis (7.1%) CPK increased (9.5%) Nausea (7.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/31786154
15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf
15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000MedR.pdf	Disc. AE: Anemia, Vertigo... AEs leading to discontinuation/dose reduction: Anemia (2 patients) Vertigo (2 patients) Bronchitis (2 patients) ALT increased (2 patients) Aspartate aminotransferase increased (3 patients) Increased serum creatinine (2 patients) Headache (2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000MedR.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2B6 926 CYP2C19 2057 P-gp 1741 BCRP 910 BSEP 550 OATP1B1 1079 OATP1B3 961 OCT1 620 OCT2 779 OAT1 725 OAT3 747 MATE1 415 MATE2 267	CYP3A5 446 P-gp 2052 BCRP 697 OATP1B1 503 OATP1B3 435 OCT1 393	CYP1A2 832 CYP2B6 669 CYP3A 142

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=18 Page: 17, 23	minor
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85	no [IC50 181 uM]	weak (co-administration study) Comment: Clinically no meaningful effect on midazolam (sensitive CYP3A4 substrate), Coadministration of Upadacitinib (30 mg QD extended-release) decreased Cmax by 16% and AUCinf by 26%., IC50=181 mcM (midazolam) and 212 mcM (teststerone), Upadacitinib caused no detectable time-dependent inhibition of any isoform tested upto a concentration of 50 µM. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85	no [IC50 40.3 uM]	no (co-administration study) Comment: Clinically no meaningful effect on S-warffarin (sensitive CYP2C9 substrate), Coadministration of Upadacitinib (30 mg QD extended-release) increased Cmax by 7% and AUCinf by 11%., Upadacitinib caused no detectable time-dependent inhibition of any isoform tested up to a concentration of 50 µM. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85	no [IC50 >250 uM]	no (co-administration study) Comment: Clinically no meaningful effect on omeprazole (sensitive CYP2C19 substrate), Coadministration of Upadacitinib (30 mg QD extended-release) increased AUCinf Ratio (5-OH OME to OME metabolic ratio) by 9%., Upadacitinib caused no detectable time-dependent inhibition of any isoform tested up to a concentration of 50 µM. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85	no [IC50 >250 uM]	no (co-administration study) Comment: Clinically no meaningful effect on dextromethorphan (sensitive CYP2D6 substrate), Coadministration of Upadacitinib (30 mg QD extended-release) increased Cmax by 9% and AUCinf by 7%., Upadacitinib caused no detectable time-dependent inhibition of any isoform tested up to a concentration of 50 µM. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85	no [IC50 >250 uM]	weak (co-administration study) Comment: Clinically no meaningful effect on caffeine (sensitive CYP1A2 substrate), Coadministration of Upadacitinib (30 mg QD extended-release) increased Cmax by 13% and AUCinf by 22%., Upadacitinib caused no detectable time-dependent inhibition of any isoform tested up to a concentration of 50 µM. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 77-85
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 87-89	no [IC50 >250 uM]	weak (co-administration study) Comment: Clinically no meaningful effect on bupropion (CYP2B6 substrate), Coadministration of Upadacitinib (30 mg QD extended-release) decreased Cmax by 13.2% and AUCinf by 7.6%., Upadacitinib caused no detectable time-dependent inhibition of any isoform tested up to a concentration of 50 µM. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=20 Page: 11, 18, 19, 23, 87-89
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	unlikely [IC50 10 uM]
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	unlikely [IC50 10 uM]
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=18 Page: 17, 23	unlikely [IC50 120 uM]
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	unlikely [IC50 220 uM]
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	unlikely [IC50 35 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=18 Page: 17, 23	unlikely [IC50 48 uM]
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=18 Page: 17, 23	unlikely [IC50 510 uM]
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	unlikely [IC50 >30 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	unlikely [IC50 >30 uM]
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	unlikely [IC50 >30 uM]
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	unlikely [IC50 >30 uM]
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=18 Page: 17, 23	yes
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=18 Page: 17, 23	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=6 Page: 5, 10, 17, 18, 23, 70-72	major	yes (co-administration study) Comment: When upadacitinib was co-administered with ketoconazole (a strong CYP3A4 inhibitor, 400 mg QD x 6 days), upadacitinib exposure increased by 75% for AUC0-inf and 70% for Cmax. Upadacitinib should be used with caution if patients receive chronic treatment with strong CYP3A4 inhibitors. When upadacitinib was co-administered with rifampin (a strong CYP3A4 inducer, 600 mg QD x 9 days), upadacitinib exposure decreased by 61% for AUC0-inf and 51% for Cmax. Upadacitinib is not recommended to be co-administered with strong CYP3A4 inducers. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=6 Page: 5, 10, 17, 18, 23, 70-72
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=6 Page: 5, 11, 17	minor
CYP3A5 446	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=23; https://www.pmda.go.jp/drugs/2020/P20200120001/112130000_30200AMX00028_I101_2.pdf#page=18 Page: 22-23, (PMD) 18	minor
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	no
OCT1 393	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=24 Page: 23.0	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=12 Page: 11, 18, 23	no	no (co-administration study) Comment: OATP1B inhibitor (rifampin, 600 mg SD) do not have clinically meaningful effect on upadacitinib PK (increased Cmax by 14% and AUCinf by 7%). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=12 Page: 11, 18, 23
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=11 Page: 10, 17, 23	yes
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf#page=11 Page: 10, 17, 23	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000PharmR.pdf#page=49 Page: 20.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA01E0RQ	https://www.aablocks.com/goods/Goods/detail?id=AA01E0RQ
Aaron Chemicals	AR01E1JI	http://www.aaronchem.com/1310726-60-3
abcr GmbH	AB514878	http://www.abcr.com/shop/en/AB514878
Achemtek	0102-032615	http://achemtek.com/1310726-60-3-2
Acorn PharmaTech	ACN-052823	http://www.acornpharmatech.com/
Ambeed	A165008	https://www.ambeed.com/products/1310726-60-3.html
BioChemPartner	BCP19011	http://www.biochempartner.com/1310726-60-3-BCP19011
Chem Scene	CS-6150	http://www.chemscene.com/1310726-60-3.html
ChemFish Tokyo co.,ltd	58557659	http://www.chemfish.co.jp/index.php?id=2929&project=product
Chemspace	CSSB00103150878	https://chem-space.com/CSSB00103150878
CSNpharm	CSN18721	https://www.csnpharm.com/products/upadacitinib.html
DC Chemicals	DC10431	http://www.dcchemicals.com/product_show-Upadacitinib.html
eNovation Chemicals	Y0975799	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0975799
Excenen	EX-A1628	http://www.excenen.com/searchresultlist.php?id=1310726-60-3
Hairui	UPXF018	http://www.hairuichem.com/en/product/1310726-60-3.html
iChemical	EBD4040026	http://www.ichemical.com/products/1310726-60-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN03250514	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN03250514
MedChem Express	HY-19569	https://www.medchemexpress.com/Upadacitinib.html
Selleck Chemicals	S8162	http://www.selleckchem.com/products/upadacitinib.html
Smolecule	S546407	http://www.smolecule.com/products/s546407
Synblock Inc	SB19218	http://www.synblock.com/product/1310726-60-3.html
THE BioTek	bt-285013	https://www.thebiotek.com/product/inhibitors/bt-285013

PubMed

Title	Date	PubMed
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.	2018-08	29076110
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.	2016-12	27390150
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.	2016-12	27389975
Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.	2016-12	27272171

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose of RINVOQ (Upadacitinib) is 15 mg once daily.

Route of Administration: Oral

In Vitro Use Guide

Upadacitinib is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:22:44 GMT 2025` Edited by `admin` on `Mon Mar 31 22:22:44 GMT 2025`
Record UNII	7KCW9IQM02
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ABT-494 TARTRATE TETRAHYDRATE

Preferred Name

English

UPADACITINIB TARTRATE

Official Name

English

UPADACITINIB TARTRATE [USAN]

Common Name

English

UPADACITINIB TARTRATE TETRAHYDRATE

Common Name

English

1-PYRROLIDINECARBOXAMIDE, 3-ETHYL-4-(3H-IMIDAZO(1,2-A)PYRROLO(2,3-E)PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)-, (3S,4R)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE, HYDRATE (1:1:4)

Systematic Name

English

(3S,4R)-3-ETHYL-4-(3H-IMIDAZO(1,2-A)PYRROLO(2,3-E)PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE, TETRAHYDRATE

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

485415